$2.78
(Market cap
$1,781 Mln
Recently Viewed
Clear AllMarket cap
$1,781 Mln
Revenue (TTM)
$883 Mln
P/E Ratio
23.6
P/B Ratio
3.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
10.2
Debt to Equity
0.6
Book Value
$25.5
EPS
$3.7
Face value
--
Shares outstanding
22,750,198
CFO
$325.24 Mln
EBITDA
$483.84 Mln
Net Profit
$-25.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
| 2.5 | 12.1 | -4.6 | 16.9 | 28.2 | 18.8 | 6.5 |
|
BSE Sensex
| -7.3 | 4.0 | -6.1 | 1.9 | 9.1 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
| 42.8 | 0.3 | 37.1 | -12.7 | 58.7 | -52.9 | 37.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ANI Pharmaceuticals (ANIP)
|
80.9 | 1,781.1 | 883.4 | 78.3 | 15.2 | 16.2 | 23.6 | 3.3 |
| 13.9 | 4,185.3 | 3,018.8 | 72.1 | 12.6 | -80 | 59.6 | 105.4 | |
| 40.9 | 5,222.3 | 1,003.8 | 22.4 | 6.8 | 7.5 | 226.9 | 14.1 | |
| 189.0 | 9,421.4 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 106.7 | |
| 76.8 | 15,107.7 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.2 | 4,646.4 | 761.4 | 99.7 | 7.3 | 15 | 53.3 | 7.1 | |
| 13.4 | 10,903.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 17.9 | 2.7 | |
| 23.7 | 11,550.7 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.7 | 6,866.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.1 | 0.9 | |
| 232.9 | 4,633.1 | 268.1 | 124.5 | 60.0 | 13.5 | 37.9 | 4.2 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel,... as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. Address: 210 Main Street West, Baudette, MN, United States, 56623 Read more
President, CEO & Director
Mr. Nikhil Lalwani
President, CEO & Director
Mr. Nikhil Lalwani
Headquarters
Baudette, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ANI Pharmaceuticals Inc (ANIP) is $80.85 (NASDAQ) as of 17-Apr-2026 16:00 EDT. ANI Pharmaceuticals Inc (ANIP) has given a return of 28.18% in the last 3 years.
The P/E ratio of ANI Pharmaceuticals Inc (ANIP) is 23.58 times as on 15-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
21.39
|
3.10
|
|
2024
|
-58.03
|
2.51
|
|
2023
|
56.43
|
2.32
|
|
2022
|
-13.71
|
1.94
|
|
2021
|
-15.34
|
1.82
|
The 52-week high and low of ANI Pharmaceuticals Inc (ANIP) are Rs 99.50 and Rs 56.71 as of 19-Apr-2026.
ANI Pharmaceuticals Inc (ANIP) has a market capitalisation of $ 1,781 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ANI Pharmaceuticals Inc (ANIP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.